Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Moderate — cranberry has repeated meta-analytic support; the probiotic and herbal components are thinner
What FemiCore Claims To Be
FemiCore is marketed to women as a “bladder reset” — a daily capsule aimed at urinary comfort, urgency, and keeping the urinary tract’s bacterial environment in balance. The underlying idea is that bladder discomfort in women is often a downstream problem of which bacteria are colonising the urogenital tract, and that you can influence that with a mix of plant compounds and specific Lactobacillus strains.
That framing is not made up. It matches how urologists and infectious-disease researchers have been thinking about recurrent urinary problems for the past decade, as antibiotic resistance pushed attention toward prevention rather than repeated treatment.
What’s Actually In It
FemiCore names nine ingredients:
- Cranberry extract
- Bearberry (Arctostaphylos uva-ursi)
- Berberine
- Mimosa pudica
- Lactobacillus crispatus
- Lactobacillus acidophilus
- Lactobacillus plantarum
- Lactobacillus gasseri
- Lactobacillus casei
No per-ingredient doses are published, and no total CFU count is given for the probiotic portion. For cranberry in particular this is a meaningful gap — the trials below hinge on proanthocyanidin content, and there is no way to compare an undisclosed extract to them.
What The Research Shows
Based on articles retrieved from PubMed, the ingredient with the strongest hand here is cranberry, and it is a genuinely decent hand.
Cranberry reduces urinary tract infection recurrence by roughly a quarter to a third. A meta-analysis restricted to otherwise healthy, non-pregnant adult women with a history of UTI — seven randomized controlled trials, 1,498 participants — found cranberry cut the risk of recurrence by 26%. The reviewers were candid that heterogeneity was substantial and most of the included trials were small, with only two enrolling more than 300 people. DOI
A larger, broader analysis reached the same conclusion — and found the delivery format matters. Pooling 23 trials and 3,979 participants across several susceptible groups, cranberry products reduced UTI incidence overall (risk ratio 0.70), with a 32% relative risk reduction specifically in women with recurrent UTIs. Notably, the subgroup analysis found juice outperformed capsules and tablets by a meaningful margin — a result that cuts directly against a capsule product. DOI
Not every Lactobacillus strain is equal, and the good news for L. crispatus is qualified. A review of non-antibiotic UTI prophylaxis concluded that different lactobacilli strains produce genuinely different results, and singled out L. crispatus as “promising” — but the promising evidence was for intravaginal suppositories in premenopausal women, not oral capsules. The same review found cranberry products cut recurrences by about 30-40% while remaining less effective than low-dose antibiotic prophylaxis, and noted the optimal cranberry dose has still not been established. DOI
Bearberry is traditional, not proven. Uva-ursi leaf is sold as a cystitis treatment across several European countries, but as of the design of a recent multicentre randomized trial, its efficacy had never been compared head-to-head against standard antimicrobial therapy. Researchers built a 504-patient double-blind trial specifically because that comparison did not yet exist. Antimicrobial activity has been shown for its extracts and constituents in the lab; clinical superiority or non-inferiority remains an open question. DOI
The Honest Verdict
What holds up: Cranberry’s prevention effect in women with recurrent urinary problems has now survived multiple independent meta-analyses. It is one of the better-supported botanicals in the entire women’s-health supplement category. The Lactobacillus strains included are well-characterised, have long safety records, and the microbiome rationale behind the product is scientifically coherent rather than invented.
What doesn’t: Two specific findings work against this product’s format. First, the largest cranberry meta-analysis found capsules and tablets underperformed juice. Second, the strongest L. crispatus data comes from vaginal suppositories, not swallowed capsules — the route of administration is doing real work in those results, and an oral capsule is not the same intervention. Bearberry’s clinical evidence is still pending. And with no doses or CFU counts disclosed, matching this formula to any trial is guesswork.
Who this makes sense for: A woman prone to recurrent urinary discomfort who is already working with a clinician, wants a preventive daily habit alongside the basics (hydration, hygiene, timely care), and understands she is buying a modest risk reduction rather than protection.
Who should skip it: Anyone with an active infection. Urinary infections that go untreated can move to the kidneys, and no supplement substitutes for a urine culture and appropriate antibiotics. Also skip if you are pregnant, on blood thinners (cranberry can interact with warfarin), or hoping this will resolve incontinence or overactive bladder — those are different conditions with different evidence bases entirely.
Check current pricing and availability
View FemiCore on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your physician before starting any supplement, especially if you have a diagnosed condition or take medication.
Research cited via PubMed: